WAYNE, PA — Cagent Vascular recently announced a significant leadership transition with Brian Walsh being appointed as the new Chief Executive Officer. Having served as the Chairman of the Board since March 2018, Walsh will take over the role from Carol Burns, continuing his leadership duties on the board while steering the company towards its next growth phase.
Walsh’s extensive background in the medical device sector, including his most recent role as Head of Carl Zeiss Meditech Cataract Technology and his leadership positions at IanTECH Medical, Inc., and Transcend Medical, Inc., equips him with over 25 years of experience in marketing, sales, and executive leadership. These roles have prepared him to lead Cagent Vascular in expanding the market presence of its flagship product, the Serranator, an innovative device designed to enhance the treatment of peripheral artery disease.
Expressing his vision for the company, Walsh stated, “Cagent Vascular is an exceptional company with a disruptive technology platform and a highly talented team.” He emphasized his commitment to leading the company through its next stage of growth, focusing on scaling up operations and driving further market adoption of its technologies.
Marc-Andre Marcotte, a board member of Cagent Vascular and Partner at Sectoral Asset Management, praised Walsh’s appointment, highlighting his unique position to advance the company given his previous executive roles and his tenure as Chairman. “Brian Walsh’s tenure as Chairman of the Board and previous executive leadership positions give him the perfect vantage point from which to take the company forward,” said Marcotte. He also thanked Carol Burns for her decade-long contribution to the company, both as co-founder and CEO, acknowledging her significant impact on the company’s development.
The leadership change comes at a crucial time for Cagent Vascular as it seeks to leverage Walsh’s experience and insights to increase the adoption of the Serranator. This product represents a critical advancement in the treatment of vascular diseases, promising to improve patient outcomes significantly.
Brian Walsh’s appointment as CEO of Cagent Vascular marks a new chapter for the company, aiming to accelerate growth and innovation in the vascular healthcare industry. With a clear focus on enhancing patient care through advanced technology, Walsh’s leadership is poised to drive Cagent Vascular towards achieving greater success in transforming the management and treatment of vascular conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.